Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 14/20 | 0.43 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CASR | P41180 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5137301 | 0.96 | BCHE (0.45) | BCHEC5AR1MEN1KMT2AEPHX2 | |
| SCHEMBL5135915 | 0.96 | BCHE (0.41) | BCHEC5AR1MEN1KMT2AEPHX2 | |
| SCHEMBL5137401 | 0.95 | CASR (0.41) | BCHEC5AR1MEN1KMT2AEPHX2 | |
| SCHEMBL5069962 | 0.92 | BCHE (0.45) | BCHEC5AR1CASRACHE | |
| SCHEMBL5136715 | 0.92 | C5AR1 (0.43) | BCHEC5AR1MEN1KMT2AEPHX2 | |
| SCHEMBL5070121 | 0.90 | SMN1; SMN2 (0.41) | BCHEC5AR1ACHE | |
| SCHEMBL5135095 | 0.90 | BCHE (0.47) | BCHEC5AR1ACHE | |
| SCHEMBL5135989 | 0.89 | SMN1; SMN2 (0.39) | BCHEC5AR1MEN1KMT2A | |
| SCHEMBL5137007 | 0.89 | DRD2 (0.38) | BCHEC5AR1CASR | |
| SCHEMBL5136313 | 0.89 | BCHE (0.43) | BCHEC5AR1MEN1KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |